Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. doi: 10.1128/AAC.48.7.2693-2696.2004.

Abstract

Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anthelmintics / pharmacology*
  • Antiviral Agents*
  • Chlorocebus aethiops
  • Fluorescent Antibody Technique
  • Niclosamide / pharmacology*
  • SARS Virus / drug effects*
  • Vero Cells
  • Virus Replication / drug effects*

Substances

  • Anthelmintics
  • Antiviral Agents
  • Niclosamide